- Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsApnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.
- MapLight shares sink on mixed phase 2 schizophrenia readoutMapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.